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Background: Fungal infections caused by Cryptococcus neoformans are a serious health concern for 
immunocompromised patients worldwide, and occasionally in immunocompetent subjects. Low-dose 
fluconazole and itraconazole are used as long-term maintenance therapy for cryptococcosis, whereas 
voriconazole and posaconazole are used as consolidation therapy. Many recent studies indicate that 
the widespread use of azoles, mainly fluconazole, is associated with the emergence of drug-resistant 
isolates, and related treatment failures. Besides, C.neoformans is intrinsically resistant to 
echinocandins and, to date, there are very few molecules with any activity towards C.neoformans, 
leading to heightened interest in finding new alternatives to conventional drugs for the treatment of 
mycosis caused by this yeast. Currently, new trends in drug discovery are represented by natural 
products from plants, or their extracts. Particularly, great interest in essential oils (EOs) as potential 
natural and economic alternatives or as adjuvants to conventional antifungal agents has emerged in 
recent years. In this study, we evaluated the antifungal activity of fluconazole, itraconazole and 
voriconazole in comparison with nine different EOs (fennel, lavender, lemon balm, pine, sage, thyme 
red-thymol chemotype, clove, oregano, geranium), and their main components (citronellal, ɣ-terpinene, 
linalylacetate, and terpinen-4-ol), against azole susceptible and not-susceptible C.neoformans 
isolates. Then, we investigated the effect of the association of itraconazole with EOs and EO 
components against C.neoformans isolates. 
Material/methods: Seven C.neoformans sensu lato clinical isolates from HIV-infected patients were 
tested. The CLSI broth microdilution method was used to evaluate the susceptibility of C.neoformans 
either to azoles or to essential oils and their components, with some modifications for EO and 
components. EOs composition was analysed by GC-MS. The chequerboard method was used for 
combination studies.
Results: Six C.neoformans isolates were susceptible to azoles, while one C.neoformans exhibited a 
reduced susceptibility to all tested azole drugs. Pine, oregano, clove, and thyme red EOs exhibited the 
highest antifungal activity with low MIC values. Among components, thymol, carvacrol, and α-pinene 
were high effective against C.neoformans. The results showed synergistic interactions (FICI<0.5) 
between itraconazole and oregano, pine, or thyme red against azole susceptible C.neoformans 
isolates. As regards the azole not-susceptible C.neoformans isolate, the synergistic effect with 
itraconazole was only observed with thyme red oil. Carvacrol was the most effective component, since 
strongly enhanced itraconazole activity against all C.neoformans isolates.
Conclusions: The results suggest that some EOs display high antifungal activity against 
C.neoformans, and suggest the potential effectiveness of thyme red, oregano EOs, and carvacrol, as 
adjuvants in combination with itraconazole. Further in-depth studies of the modes of action for 
synergistic combinations as well as in vivo preclinical models are encouraged to predict the 
translational use of these data for clinical settings. 
